STOK Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. (STOK) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 77% planned / 23% discretionary
Largest single sale: $1.3M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Ticho Barry 2 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 5,545 | $30.67 | $170.1K | 21,710 −20.3% of holding | |
| Kaye Edward M. MD 2 fills | Director | Sell | 12,567 | $32.03 | $402.5K | 125,194 −9.1% of holding | |
| Ticho Barry 2 fills | CHIEF MEDICAL OFFICER | Sell | 4,767 | $32.03 | $152.7K | 25,897 −15.5% of holding | |
| Allan Jonathan 2 fills | GENERAL COUNSEL & CORP SEC | Sell | 2,861 | $32.03 | $91.6K | 21,370 −11.8% of holding | |
| Ticho Barry 2 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 7,176 | $29.04 | $208.4K | 21,691 −24.9% of holding | |
| Ticho Barry 2 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 7,228 | $32.66 | $236.1K | 28,098 −20.5% of holding | |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC | Sell 10b5-1 | 1,457 | $29.95 | $43.6K | 18,086 −7.5% of holding | |
| Ticho Barry | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 1,795 | $30.58 | $54.9K | 34,826 −4.9% of holding | |
| Ticho Barry | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 2,243 | $32.79 | $73.5K | 36,621 −5.8% of holding | |
| Ticho Barry | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 1,838 | $32.66 | $60.0K | 38,864 −4.5% of holding | |
| Allan Jonathan 2 fills | GENERAL COUNSEL & CORP SEC | Sell 10b5-1 | 9,293 | $33.69 | $313.0K | 20,144 −31.6% of holding | |
| Ticho Barry | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 1,461 | $29.99 | $43.8K | 40,702 −3.5% of holding | |
| Ticho Barry 3 fills | CHIEF MEDICAL OFFICER | Sell | 6,686 | $31.34 | $209.6K | 41,384 −13.9% of holding | |
| Allan Jonathan 3 fills | GENERAL COUNSEL & CORP SEC | Sell | 4,628 | $31.34 | $145.1K | 29,242 −13.7% of holding | |
| Leggett Thomas 3 fills | Chief Financial Officer | Sell | 2,382 | $31.34 | $74.7K | 10,381 −18.7% of holding | |
| Hoitt Jason 3 fills | Chief Patient Officer | Sell | 1,931 | $31.34 | $60.5K | 10,445 −15.6% of holding | |
| Ticho Barry 2 fills | CHIEF MEDICAL OFFICER | Sell | 6,164 | $33.01 | $203.5K | 50,071 −11% of holding | |
| Allan Jonathan 2 fills | GENERAL COUNSEL & CORP SEC | Sell | 4,267 | $33.01 | $140.8K | 35,255 −10.8% of holding | |
| Leggett Thomas 2 fills | Chief Financial Officer | Sell | 2,196 | $33.01 | $72.5K | 13,476 −14% of holding | |
| Hoitt Jason 2 fills | Chief Patient Officer | Sell | 1,781 | $33.01 | $58.8K | 12,955 −12.1% of holding | |
| LEVIN ARTHUR A | Director | Sell 10b5-1 | 605 | $36.80 | $22.3K | 4,237 −12.5% of holding | |
| Krainer Adrian R. | Director | Sell 10b5-1 | 33,243 | $39.74 | $1.3M | 283,302 −10.5% of holding | |
| TZIANABOS ARTHUR | Interim Executive Chair | Sell 10b5-1 | 4,355 | $40.00 | $174.2K | 31,339 −12.2% of holding | |
| Krainer Adrian R. | Director | Sell 10b5-1 | 7,229 | $39.66 | $286.7K | 316,545 −2.2% of holding | |
| Kaye Edward M. MD 3 fills | Director | Sell 10b5-1 | 13,430 | $32.27 | $433.4K | 58,729 −18.6% of holding | |
| Allan Jonathan 2 fills | GENERAL COUNSEL & CORP SEC | Sell 10b5-1 | 3,978 | $32.28 | $128.4K | 14,509 −21.5% of holding | |
| Allan Jonathan 2 fills | GENERAL COUNSEL & CORP SEC | Sell 10b5-1 | 7,781 | $31.29 | $243.4K | 18,153 −30% of holding | |
| Kaye Edward M. MD | Director | Sell | 6,367 | $31.33 | $199.5K | 64,735 −9% of holding | |
| Kaye Edward M. MD 2 fills | Director | Sell 10b5-1 | 2,181 | $31.31 | $68.3K | 63,054 −3.3% of holding | |
| Ticho Barry | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 1,989 | $31.35 | $62.3K | 19,798 −9.1% of holding | |
| Ticho Barry | CHIEF MEDICAL OFFICER | Sell | 1,673 | $31.33 | $52.4K | 21,787 −7.1% of holding | |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC | Sell | 1,004 | $31.33 | $31.5K | 23,590 −4.1% of holding | |
| Kaye Edward M. MD 2 fills | Director | Sell | 6,453 | $30.87 | $199.2K | 72,333 −8.2% of holding | |
| Ticho Barry 2 fills | CHIEF MEDICAL OFFICER | Sell | 1,696 | $30.87 | $52.4K | 23,783 −6.7% of holding | |
| Allan Jonathan 2 fills | GENERAL COUNSEL & CORP SEC | Sell | 1,018 | $30.87 | $31.4K | 24,788 −3.9% of holding | |
| Allan Jonathan 2 fills | GENERAL COUNSEL & CORP SEC | Sell | 2,292 | $30.65 | $70.2K | 21,006 −9.8% of holding | |
| Ticho Barry 2 fills | CHIEF MEDICAL OFFICER | Sell | 2,014 | $30.65 | $61.7K | 16,381 −10.9% of holding | |
| Kaye Edward M. MD 2 fills | Director | Sell | 1,070 | $30.65 | $32.8K | 51,956 −2% of holding | |
| Allan Jonathan 2 fills | GENERAL COUNSEL & CORP SEC | Sell | 2,284 | $29.78 | $68.0K | 22,772 −9.1% of holding | |
| Ticho Barry 2 fills | CHIEF MEDICAL OFFICER | Sell | 2,006 | $29.78 | $59.7K | 17,932 −10.1% of holding | |
| Kaye Edward M. MD 2 fills | Director | Sell | 1,066 | $29.78 | $31.7K | 52,780 −2% of holding | |
| Krainer Adrian R. | Director | Sell 10b5-1 | 40,472 | $29.72 | $1.2M | 323,774 −11.1% of holding | |
| Krainer Adrian R. 2 fills | Director | Sell 10b5-1 | 40,472 | $26.98 | $1.1M | 384,928 −9.5% of holding | |
| Ticho Barry 4 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 5,931 | $25.72 | $152.6K | 9,350 −38.8% of holding | |
| Kaye Edward M. MD | Director | Sell 10b5-1 | 25,000 | $30.00 | $750.0K | 49,124 −33.7% of holding | |
| Kaye Edward M. MD | Director | Sell 10b5-1 | 42,461 | $25.09 | $1.1M | 49,124 −46.4% of holding | |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC | Sell 10b5-1 | 10,000 | $25.07 | $250.7K | 11,831 −45.8% of holding | |
| Ticho Barry | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 5,343 | $23.64 | $126.3K | 13,126 −28.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.